Dr. Hua is a seasoned drug developer who has 20 years’ global clinical development and new drug registration experience with track records. Prior to founding BioNova, Dr. Hua was Senior VP, Head of Clinical Development and Regulatory Affairs at Hutchison MediPharma where he built up a development organization of 80+ employees across seven line functions with sites in Shanghai, Beijing, Guangzhou, Melbourne Australia and New Jersey USA. During his tenure at Hutchison MediPharma, Dr. Hua rapidly expanded development pipeline from five small molecules seven Phase 1 trials to eight small molecules for which half assets advanced to pivotal/registration trials. Dr. Hua led fruquintinib NDA submission in mCRC indication via MAH pilot policy in China and received regulatory approval. Native from Shanghai, Dr. Hua graduated from Fudan University Shanghai Medical College in 1992. He spent 16 years in the US in the field of clinical development with most significant achievements being regulatory submission and approval of Humira, Reclast/Aclasta, Zometa, Revlimid and Pomalyst.

Dr. Huang brings more than 20 years’ experience in medical research, pharmaceutic drug development and healthcare investment banking. Prior to co-founding BioNova, Dr. Huang was the Head of Business Development and Strategy at Immunomedics, responsible for all collaborations, licensing and acquisitions as well as development and portfolio strategy. Dr. Huang was previously BD and Portfolio Strategy Lead at Celgene for hematology and oncology franchise. He also worked as biotech equity analyst before joining pharmaceutical industry, covering 50+ companies across a variety of therapeutic areas with enstensive experience in primary and secondary stock underwriting and BD transactions totaled more than $20B.

Winnie joined BioNova as Head of Operations in 2019. Under her leadership in talent acquisition and office administration, BioNova has advanced to fast growth stage with well-balanced staffing situation. Winnie has more than 10 years of pharmaceutical industry experience. Prior to joining BioNova, Winnie was HR & Admin manager at Pivotal BioVenture Partners where she was responsible for company payroll, employee relationship, talent management, Culture and team building, government affairs, general administration and IT management. Practiced in labor law and building HR working process. Earlier in her career, Winnie worked in the HR field at I-Bridge Capital and Hutchsion MediPharma. Winnie received a Bachelor Degree in Business Administration from Shanghai Normal University.

Yu joined BioNova in early 2020. As a card-carrying hematologist, Yu successfully led the cGVHD project IND filing and subsequently received Breakthrough Designation in China. Yu graduated from Tongji Medical College, Huazhong University of Science and Technology. She specialized in hematology and worked as resident and attending physician for 8 years prior to joining the pharmaceutical industry. Then she worked in Sanofi, Roche, Hutchison and Fosunkite. Through many years of extensive experience, as a physician scientist, Yu devoted in clinical development for target therapies and CAR-T cell therapy for hematologic malignancies, effective leader of cross-functional teams driving complex projects and solving multifaceted problem, and successfully led the clinical development program and the NDA filing of Yescarta, which is the first approved CAR-T cell therapy in China.

Peng joinined BioNova in early 2021. He has more than 15 years’ experience in CMC research and development, having led more than a dozen drugs to go through different research stages (IND-NDA). Works closely with cross-functional, and at the corporate level(including R&D，clinical operation, clinical affairs and quality assurance) to identify issues that may impact project milestone or business operations, and recommends appropriate action to be taken. Lead CMC development at different stages of process development, formulation development, clinical trial manufacturing, product characterization and process validation. Set up Quality Management System as well as monitoring and optimizing the system. Prior to Joining BioNova, Peng worked at AnHeart and Haihe BioPharma. Peng graduated from East China University of Science and Technology.

Jenny joinined BioNova in early 2021. She graduated from University of Liverpool with the Bachelor of Science and obtained Master of Science degree from McGill University. Prior to joining BioNova, Jenny was senior project manager at Jiangsu Hengrui Medicine, responsible for IND-enabling projects including designed, executed and interpreted non-clinical pharmacology, ADME and toxicology studies, and completed the IND and NDA for several new drugs.

Fang joined BioNova in September 2021. She has over 10 years of translational medicine experience including extensive experience in biomarker development for immuno-oncology and cell therapy. Prior to joining BioNova, Fang worked as Biomarker Leader at Innovent and BeiGene and supported several mAbs, bispecific antibodies and small molecules’ clinical development. Before BeiGene, Fang served as Research Scientist at Cellular Biomedicine Group and Institute Merieux (BioMerieux and Transgene), focusing on biomarker and bioassay discovery, development and testing. Fang holds a Ph.D. in Pharmacology from Shanghai Jiao Tong University and a Bachelor’s degree of Clinical Medicine from Jilin Medical College.

Dr. Huang graduated from Shanghai Jiao Tong University (PhD), and Shanghai Institute of Pharmaceutical Industry (MS). He has more than 20 years’ comprehensive experience in the pharmaceutical industry, including in regulatory affairs, CMC quality, clinical trial, project management, and R&D operations.

Prior to joining BioNova, Dr. Huang was former R&D Deputy General Manager at Sinopharm Shanghai Shyndec Pharmaceutical, and former Head of Regulatory Affairs at Aurobindo Pharma (China) and TYK Medicines. He led the development and market authorization applications for over a dozen generic drugs in China as well as China & US IND applications for multiple innovative new drugs.

Dr. Wen-Lian Wu has more than 25 years’ experience and profound track records in drug discovery in the pharmaceutical industry (20 years at large pharma and 5 years as co-founder at start-up).  His expertise encompasses broad therapeutic areas from central nervous system (CNS), oncology and immune-oncology, cardiovascular to metabolic diseases. Dr. Wu has deep knowledge in small molecule drug design and synthesis compounded with expert-level skills in small molecule intellectual property strategy and execution.  To date, Dr. Wu has published / filed over 100 papers, abstracts, patent application or conference presentations.